lncRNA IUR upregulates miR‑34a to inhibit pancreatic adenocarcinoma cell migratory and invasive abilities

Li,Ren; Zhang,Jian; Ma,Shiyang; Zhao,Gang; Li,Jun; Li,Jiangwei; Wang,Xiaoyi; Hui,Bo

doi:10.3892/ol.2021.12828

July-2021 Volume 22 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2021 Volume 22 Issue 1

Full Size Image

Article Open Access

lncRNA IUR upregulates miR‑34a to inhibit pancreatic adenocarcinoma cell migratory and invasive abilities

Authors:
- Ren Li
- Jian Zhang
- Shiyang Ma
- Gang Zhao
- Jun Li
- Jiangwei Li
- Xiaoyi Wang
- Bo Hui
View Affiliations / Copyright

Affiliations: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, National and Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China

Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 567
|
Published online on: May 29, 2021

https://doi.org/10.3892/ol.2021.12828
Expand metrics +

Abstract

The long non‑coding RNA (lncRNA) imatinib‑upregulated (IUR) has been recently reported as a tumor suppressor in leukemia. Preliminary microarray data revealed a downregulation of IUR in pancreatic adenocarcinoma (PAAD) and a positive correlation with microRNA‑34a (miR‑34a) expression. The present study aimed to investigate the role of IUR in PAAD. This study included samples from 58 patients with PAAD and the PAAD cell lines Capan‑2 and HPAC. Reverse transcription quantitative PCR was performed to determine gene expression levels. Cell transfections were carried out to assess gene interactions between IUR, miR‑34a and CD44. Transwell assays were performed to explore the effects of transfections on cell invasive and migratory abilities. The results demonstrated that IUR was downregulated in PAAD tissue compared with adjacent non‑tumor tissue samples and that low expression levels of IUR correlated with poor survival in patients with PAAD. In PAAD tissue samples, the expression of IUR positively correlated with miR‑34a expression but negatively correlated with CD44 expression, which is a target of miR‑34a. In PAAD cells, overexpression of IUR resulted in miR‑34a upregulation and CD44 downregulation. miR‑34a overexpression did not affect the expression of IUR but downregulated CD44. In PAAD cells, overexpression of IUR and miR‑34a led to decreased invasive and migratory abilities. However, CD44 overexpression played an opposite role and attenuated the effects of IUR and miR‑34a overexpression. In conclusion, the results from this study demonstrated that IUR may upregulate miR‑34a expression in order to inhibit PAAD cell migration and invasion by downregulating CD44.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Luberice K, Downs D, Sadowitz B, Ross S and Rosemurgy A: Has survival improved following resection for pancreatic adenocarcinoma? Am J Surg. 214:341–346. 2017. View Article : Google Scholar : PubMed/NCBI
4	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014. View Article : Google Scholar : PubMed/NCBI
5	Nickel F, Haney CM, Kowalewski KF, Probst P, Limen EF, Kalkum E, Diener MK, Strobel O, Müller-Stich BP and Hackert T: Laparoscopic versus open pancreaticoduodenectomy: A systematic review and meta-analysis of randomized controlled trials. Ann Surg. 271:54–66. 2020. View Article : Google Scholar : PubMed/NCBI
6	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016. View Article : Google Scholar : PubMed/NCBI
7	Amundadottir LT: Pancreatic cancer genetics. Int J Biol Sci. 12:314–325. 2016. View Article : Google Scholar : PubMed/NCBI
8	Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell. 61:1303–1313. 1990. View Article : Google Scholar : PubMed/NCBI
9	Senbanjo LT and Chellaiah MA: CD44: A multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 5:182017. View Article : Google Scholar : PubMed/NCBI
10	Jiang W, Zhang Y, Kane KT, Collins MA, Simeone DM, di Magliano MP and Nguyen KT: CD44 regulates pancreatic cancer invasion through MT1-MMP. Mol Cancer Res. 13:9–15. 2015. View Article : Google Scholar : PubMed/NCBI
11	Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
12	Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S and Scaria V: Systematic transcriptome wide analysis of lncRNA-miRNA interactions. PLoS One. 8:e538232013. View Article : Google Scholar : PubMed/NCBI
13	Li H, Xu Y, Wang G, Chen X, Liang W and Ni H: Long non-coding RNA Mirt2 relieves lipopolysaccharide-induced injury in PC12 cells by suppressing miR-429. J Physiol Biochem. 75:403–413. 2019. View Article : Google Scholar : PubMed/NCBI
14	Appel BL, Tolat P, Evans DB and Tsai S: Current staging systems for pancreatic cancer. Cancer J. 18:539–549. 2012. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ilic M and Ilic I: Epidemiology of pancreatic cancer. World J Gastroenterol. 22:9694–9705. 2016. View Article : Google Scholar : PubMed/NCBI
18	Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol. 21:2807–2815. 2015. View Article : Google Scholar : PubMed/NCBI
19	Li H, Rokavec M and Hermeking H: Soluble IL6R represents a miR-34a target: Potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop. Oncotarget. 6:14026–14032. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

lncRNA IUR upregulates miR‑34a to inhibit pancreatic adenocarcinoma cell migratory and invasive abilities

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles